• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Research
  • Biotech
    • Clinical Data
    • Venture Capital
    • Deals
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending Topics
    • Cell & Gene Therapy
    • COVID-19
  • Podcasts
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Research
  • Biotech
    • Clinical Data
    • Venture Capital
    • Deals
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending Topics
    • Cell & Gene Therapy
    • COVID-19
  • Podcasts
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Galera Therapeutics

picture of a paraglider
Biotech

Novartis R&D chief Jay Bradner departs—Chutes & Ladders

Novartis R&D chief Bradner to depart after seven years. Pfizer fills first chief marketing officer role. I-Mab sneaks two exec changes into earnings.
Max Bayer , Gabrielle Masson Sep 2, 2022 9:30am
Clinician research scientific data analysis

Galera shares rise over 100% as phase 3 flop deemed an error

Dec 14, 2021 3:30pm
Cancer Care

Galera shares slide as radiotherapy complication drug fails

Oct 19, 2021 11:53am
greenlight

Galera reels in $150M to test radiation side effect med in phase 3

Sep 19, 2018 11:10am
cancer

Poised for phase 3, Galera's GC4419 wards off radiation side effects

Aug 20, 2018 5:00am
Home
  • Connect
    • The Team
    • Advertise
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2023 Questex LLC All rights reserved.
Terms of use
Privacy Policy